SAN DIEGO, Oct. 4, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that Dr. Richard Martin, Vice President, Chemistry, will present an overview of the Company's NexACT® technology at the Partnership Opportunities In Drug Delivery ("PODD") Conference (http://www.theconferenceforum.org/PartnershipOpportunitiesInDrugDelivery-Overview.html) today, Tuesday, October 4, 2011, at the Omni Parker House Hotel in Boston Massachusetts. Dr. Martin's presentation will be a part of the Small Molecule Panel and will be given between 1:45 pm and 5:30 pm ET.
During the panel, Dr. Martin will provide an overview of the Company's NexACT® technology, including its leading molecule -- dodecyl-2-N, N-dimethylamino propionate hydrochloride (DDAIP.HCI) -- which has been listed in various regulatory filings as a functional non-active excipient. Dr. Martin will discuss the application of this technology in the optimization of pharmacokinetic parameters of given drugs, and the Company's belief that NexACT® has tremendous commercial potential in the development of new and improved products with increased bioavailability.
Dr. Martin will also provide a description of the NexACT® technology's mechanisms of action, chemistry, toxicology and safety of the excipients, along with some typical examples of different routes of administration, such as transdermal, oral and buccal. He will further briefly discuss the Company's patent portfolio surrounding the NexACT® technology (currently 135 issued patents and 137 patent pending, worldwide applications) and the competitive advantages of the technology, which include its usefulness for both hydrophobic and hydrophilic molecules, reversible and temporary disruption of the lipid bilayer, its bio-degradable and non-toxic properties, as well as in the Company's belief, its overall superior effectiveness versus other enhancers.
About Apricus Biosciences, Inc.
Apricus Bio, a San Diego-based, revenue-generating, biopharmaceutical company, has leveraged the flexibility of its clinically-validated NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes.
Revenues and growth are driven from out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies worldwide. In addition, the Company is seeking to monetize its existing Rx Division product pipeline, including its first product, Vitaros®, approved in Canada for the treatment of erectile dysfunction, which is currently expected to be available on the Canadian market in 2011, as well as compounds in development from pre-clinical through Phase III, currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals among others.
The Company is also developing its Consumer Healthcare Division by developing a number of drugs that utilize the Company's NexACT® technology to comply with the FDA's over-the-counter ("OTC") requirements, be cleared as 510(k) topical creams that are considered to be medical devices or approved as Abbreviated New Drug Applications ("ANDAs") as generic drugs. The Company will also seek to market such drugs through these similar procedures in foreign countries.
For further information on Apricus Bio, visit http://www.apricusbio.com and for information on its subsidiary please visit www.nexmedusa.com. Information may also be found at http://twitter.com/apricusbio, and http://facebook.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to receive issued patents on its NexACT® technology and products, develop such patented technology into product candidates, have its Rx Division products and product candidates approved by relevant regulatory authorities and its Consumer Healthcare Division products either approved or cleared by relevant regulatory authorities or be in compliance with appropriate regulatory requirements, to successfully manufacture and commercialize such Rx Division products along with its Consumer Healthcare Division products and product candidates and to achieve its other development, commercialization and financial goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.